361 Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

361 Capital’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-72,030	Closed	-$1.41M	–	422
2018 Q2	$1.41M	Buy	+72,030	New	+$1.59M	0.32%	195
2017 Q4	–	Sell	-10,664	Closed	-$197K	–	329
2017 Q3	$197K	Buy	+10,664	New	+$199K	0.04%	242

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

361 Capital's AMAG Position: Q3 2018 in Review

361 Capital sold out of AMAG Pharmaceuticals (AMAG) in Q3 2018, closing a stake of 72,030 shares — an estimated $1.41M sold.

361 Capital first reported a position in AMAG in Q3 2017 and held it in 2 quarters. The position peaked at $1.41M in Q2 2018. 182 funds tracked by Wall St. Rank hold AMAG as of Q3 2018.

361 Capital reported no remaining AMAG Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
361 Capital sold 72,030 AMAG Pharmaceuticals shares in Q3 2018, an estimated $1.41M.
361 Capital first reported a position in AMAG Pharmaceuticals in Q3 2017 and held it in 2 quarters.
361 Capital's AMAG Pharmaceuticals position peaked at $1.41M in Q2 2018.
182 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2018.

Based on 361 Capital's 13F filing for Q3 2018, filed 13 Nov 2018.